ECSP14014544A - Compuestos terapéuticamente activos y sus métodos de uso - Google Patents
Compuestos terapéuticamente activos y sus métodos de usoInfo
- Publication number
- ECSP14014544A ECSP14014544A ECIEPI201414544A ECPI201414544A ECSP14014544A EC SP14014544 A ECSP14014544 A EC SP14014544A EC IEPI201414544 A ECIEPI201414544 A EC IEPI201414544A EC PI201414544 A ECPI201414544 A EC PI201414544A EC SP14014544 A ECSP14014544 A EC SP14014544A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- active compounds
- therapeutically active
- idh1
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Abstract
Se proporcionan métodos para tratar un cáncer caracterizado por la presencia de un alelo mutante de IDH1/2 que comprenden administrar a un individuo que lo necesita un compuesto descrito en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012070601 | 2012-01-19 | ||
PCT/CN2013/000068 WO2013107291A1 (en) | 2012-01-19 | 2013-01-21 | Therapeutically active compounds and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP14014544A true ECSP14014544A (es) | 2015-12-31 |
Family
ID=48797706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201414544A ECSP14014544A (es) | 2012-01-19 | 2014-08-18 | Compuestos terapéuticamente activos y sus métodos de uso |
Country Status (41)
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985557B (zh) | 2009-03-13 | 2018-06-15 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
EP2448582B1 (en) | 2009-06-29 | 2017-04-19 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
HUE039269T2 (hu) | 2011-05-03 | 2018-12-28 | Agios Pharmaceuticals Inc | Piruvát-kináz aktivátorok terápiában történõ alkalmazásra |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
JP6228130B2 (ja) * | 2012-01-19 | 2017-11-08 | アジオス ファーマシューティカルズ, インコーポレイテッド | 治療活性化合物およびそれらの使用方法 |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
CN104822373B (zh) | 2012-10-15 | 2018-08-28 | 安吉奥斯医药品有限公司 | 治疗性化合物和组合物 |
PE20160744A1 (es) | 2013-07-11 | 2016-08-01 | Agios Pharmaceuticals Inc | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer |
EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015010297A1 (en) * | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
CN103694142A (zh) * | 2013-11-28 | 2014-04-02 | 浙江科技学院 | 4-N-Boc-氨基环己酮的制备方法 |
WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
AU2015229214B2 (en) * | 2014-03-14 | 2019-07-11 | Les Laboratoires Servier | Pharmaceutical compositions of therapeutically active compounds |
BR122023021436A2 (pt) * | 2014-03-14 | 2023-12-12 | Les Laboratoires Servier | Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos |
CN106661002B (zh) | 2014-08-04 | 2021-06-29 | 纽韦卢森公司 | 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的嘧啶衍生物 |
RU2692782C2 (ru) | 2014-10-01 | 2019-06-27 | Дайити Санкио Компани, Лимитед | Производное изоксазола в качестве ингибитора мутантной изоцитратдегидрогеназы 1 |
US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
KR20180061372A (ko) * | 2015-10-15 | 2018-06-07 | 아지오스 파마슈티컬스 아이엔씨. | 악성 종양의 치료를 위한 조합물 요법 |
SI3362066T1 (sl) * | 2015-10-15 | 2022-04-29 | Les Laboratoires Servier | Kombinirana terapija za zdravljenje malignosti |
EA039805B1 (ru) * | 2015-11-13 | 2022-03-15 | Аджиос Фармасьютикалз, Инк. | Комбинированная терапия для лечения злокачественных опухолей |
CA3007218A1 (en) * | 2015-12-04 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Methods of treatment of malignancies |
WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
WO2017146794A1 (en) | 2016-02-26 | 2017-08-31 | Celgene Corporation | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
PT3434671T (pt) * | 2016-03-22 | 2020-12-24 | Lianyungang Runzhong Pharmaceutical Co Ltd | Composto de sultama e método para a sua aplicação |
WO2018010142A1 (en) | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
WO2018045071A1 (en) | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
KR20200027502A (ko) * | 2017-06-12 | 2020-03-12 | 아지오스 파마슈티컬스 아이엔씨. | 병용 요법을 사용한 뇌 종양 치료 방법 |
JP7263669B2 (ja) | 2017-06-12 | 2023-04-25 | レ ラボラトワール セルヴィエ | 併用療法を用いて脳腫瘍を処置する方法 |
JP6951562B2 (ja) * | 2017-09-22 | 2021-10-20 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | 環状スルホンアミド化合物の結晶 |
EP3717470A1 (en) * | 2017-11-27 | 2020-10-07 | Assia Chemical Industries Ltd | Solid state forms of ivosidenib |
US20220057371A1 (en) * | 2018-02-19 | 2022-02-24 | The Regents Of The University Of Colorado, A Body Corporate | 6-oxo-pipecolic acid quantitation by mass spectrometry |
HUE061331T2 (hu) | 2018-05-16 | 2023-06-28 | Forma Therapeutics Inc | Mutáns IDH-1 gátlása |
US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
US10980788B2 (en) * | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
CN112367995A (zh) | 2018-07-06 | 2021-02-12 | 安吉奥斯医药品有限公司 | 艾伏尼布形式和药物组合物 |
CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN109535025B (zh) * | 2018-12-18 | 2022-09-09 | 尚科生物医药(上海)有限公司 | 一种艾伏尼布中间体3,3-二氟环丁胺盐酸盐的制备方法 |
WO2020127887A1 (en) | 2018-12-21 | 2020-06-25 | Sandoz Ag | Process for the preparation of an intermediate product of ivosidenib |
EP4010331B1 (en) | 2019-08-08 | 2023-10-04 | Les Laboratoires Servier | A method for preparing ivosidenib and an intermediate thereof |
WO2021028791A1 (en) * | 2019-08-09 | 2021-02-18 | Alembic Pharmaceuticals Limited | An improved process of preparation of ivosidenib |
TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
US20230242503A9 (en) * | 2019-08-09 | 2023-08-03 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
WO2021079380A1 (en) * | 2019-10-23 | 2021-04-29 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of (2s)-n-{(1s)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-n-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
JP2023519603A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
CN111349081B (zh) * | 2020-04-28 | 2021-01-15 | 宁波大学科学技术学院 | 一种Ivosidenib及其中间体的手性合成方法 |
CN116348145A (zh) | 2020-07-21 | 2023-06-27 | 第一三共株式会社 | 替莫唑胺和突变型idh1酶抑制剂的组合药物 |
TW202330491A (zh) * | 2021-12-30 | 2023-08-01 | 大陸商上海湃隆生物科技有限公司 | 一種DNA聚合酶theta抑制劑及其應用 |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390529A (en) | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
DE1252823B (es) | 1963-02-15 | |||
BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3867383A (en) | 1971-03-29 | 1975-02-18 | Ciba Geigy Corp | Monoanthranilatoanilino-s-triazines |
BE793501A (fr) | 1971-12-31 | 1973-06-29 | Ciba Geigy | Composes heterocycliques et produits phytopharmaceutiques qui en contiennent |
CH606334A5 (es) | 1974-06-21 | 1978-10-31 | Ciba Geigy Ag | |
DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
JPS58186682A (ja) | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
US5041443A (en) | 1989-02-21 | 1991-08-20 | Dainippon Pharmaceutical Co., Ltd. | Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof |
US5021421A (en) | 1989-03-03 | 1991-06-04 | Dainippon Pharmaceutical Co., Ltd. | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same |
JPH0491034A (ja) | 1990-08-02 | 1992-03-24 | Fujimoto Daiagunosuteitsukusu:Kk | 中枢神経保護剤 |
JPH0499768A (ja) | 1990-08-17 | 1992-03-31 | Dainippon Pharmaceut Co Ltd | 4―(4―フェニルピリジン―2―イル)ピペラジン―1―オキシド誘導体 |
JPH05140126A (ja) | 1991-11-26 | 1993-06-08 | Hokko Chem Ind Co Ltd | トリアゾール誘導体および除草剤 |
US5489591A (en) | 1992-02-28 | 1996-02-06 | Zenyaku Kogyo Kabushiki Kaisha | S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
FR2735127B1 (fr) | 1995-06-09 | 1997-08-22 | Pf Medicament | Nouvelles piperazines heteroaromatiques utiles comme medicaments. |
ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
US6313127B1 (en) | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
JPH09291034A (ja) | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
JP2000510866A (ja) | 1996-05-20 | 2000-08-22 | ダーウィン・ディスカバリー・リミテッド | Tnfとpde―ivのインヒビターとしてのキノリンスルホンアミド |
US5984882A (en) | 1996-08-19 | 1999-11-16 | Angiosonics Inc. | Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy |
EP0945446A4 (en) | 1996-11-14 | 1999-12-08 | Nissan Chemical Ind Ltd | CYANOETHYLMELAMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME |
US6399358B1 (en) | 1997-03-31 | 2002-06-04 | Thomas Jefferson University | Human gene encoding human chondroitin 6-sulfotransferase |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
DE1042305T1 (de) | 1997-12-22 | 2001-04-19 | Bayer Ag | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
WO2000002864A1 (en) | 1998-07-10 | 2000-01-20 | Martens Juergen | Precusors for pna-monomers |
ES2404074T3 (es) | 1998-08-06 | 2013-05-23 | Mountain View Pharmaceuticals, Inc. | Conjugados de peg-oxidasa de urato y su uso |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
UY25842A1 (es) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
AU5379900A (en) | 1999-06-07 | 2000-12-28 | Shire Biochem Inc. | Thiophene integrin inhibitors |
AU775625B2 (en) | 1999-08-27 | 2004-08-05 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
WO2001019788A2 (en) | 1999-09-17 | 2001-03-22 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
RU2002110295A (ru) | 1999-09-17 | 2003-12-10 | Милленниум Фармасьютикалс, Инк. (Us) | Ингибиторы фактора Ха |
JP4794793B2 (ja) | 1999-12-28 | 2011-10-19 | ファーマコペイア, インコーポレイテッド | N−ヘテロ環TNF−α発現阻害剤 |
ATE311366T1 (de) | 2000-02-29 | 2005-12-15 | Millennium Pharm Inc | Benzamide und ähnliche inhibitoren vom faktor xa |
EP1301484A2 (en) | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin receptor ligands |
JP4113323B2 (ja) | 2000-08-07 | 2008-07-09 | 富士フイルム株式会社 | アゾ色素及びそれを含むインクジェット記録用インク、並びにインクジェット記録方法 |
US6525091B2 (en) | 2001-03-07 | 2003-02-25 | Telik, Inc. | Substituted diarylureas as stimulators for Fas-mediated apoptosis |
US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
CA2445653A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
US7087614B2 (en) | 2001-06-19 | 2006-08-08 | Bristol-Myers Squibb Co. | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
WO2003016289A1 (en) | 2001-08-17 | 2003-02-27 | Ciba Specialty Chemicals Holding Inc. | Triazine derivatives and their use as sunscreens |
JP4753336B2 (ja) | 2001-09-04 | 2011-08-24 | 日本化薬株式会社 | 新規アリル化合物及びその製法 |
US6878196B2 (en) | 2002-01-15 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Ink, ink jet recording method and azo compound |
US20040067234A1 (en) | 2002-07-11 | 2004-04-08 | Paz Einat | Isocitrate dehydrogenase and uses thereof |
US7205298B2 (en) | 2002-07-18 | 2007-04-17 | Janssen Pharmaceutica N.V. | Substituted triazine kinase inhibitors |
JP2004083610A (ja) | 2002-08-22 | 2004-03-18 | Fuji Photo Film Co Ltd | インクセット、インクカートリッジ、記録方法、プリンター及び記録物 |
JP2004107220A (ja) | 2002-09-13 | 2004-04-08 | Mitsubishi Pharma Corp | TNF−α産生抑制剤 |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
US7361691B2 (en) | 2002-12-02 | 2008-04-22 | Arqule, Inc. | Method of treating cancers using β-lapachone or analogs or derivatives thereof |
NZ541050A (en) | 2002-12-16 | 2010-06-25 | Genmab As | Human monoclonal antibodies against interleukin 8 (IL-8) |
BRPI0406667A (pt) | 2003-01-10 | 2005-12-20 | Threshold Pharmaceuticals Inc | Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg |
US7358262B2 (en) | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
WO2004074438A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
ATE467616T1 (de) | 2003-04-11 | 2010-05-15 | High Point Pharmaceuticals Llc | Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase |
US7226920B2 (en) | 2003-08-06 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Aminotriazole compounds useful as inhibitors of protein kinases |
EP1689722A2 (en) | 2003-10-10 | 2006-08-16 | Bayer Pharmaceuticals Corporation | 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
JP4099768B2 (ja) | 2003-11-10 | 2008-06-11 | 富士電機デバイステクノロジー株式会社 | 電子写真感光体および該電子写真感光体に起因する干渉縞有無の判定方法 |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
CN1921864A (zh) | 2003-12-24 | 2007-02-28 | 西奥斯公司 | 使用TGF-β抑制剂治疗神经胶质瘤 |
JP2005264016A (ja) | 2004-03-19 | 2005-09-29 | Fuji Photo Film Co Ltd | インクジェット記録用インク、インクセット及びインクジェット記録方法 |
US7335770B2 (en) | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
GB0412526D0 (en) | 2004-06-05 | 2004-07-14 | Leuven K U Res & Dev | Type 2 diabetes |
CA2580845A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
AU2005286592A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
EP1924573A1 (en) | 2005-01-25 | 2008-05-28 | AstraZeneca AB | B-raf inhibitors |
PL215157B1 (pl) | 2005-04-11 | 2013-10-31 | Savient Pharmaceuticals | Wyizolowana urykaza, zawierajaca ja kompozycja farmaceutyczna, kodujacy ja wyizolowany kwas nukleinowy, zawierajacy go wektor i obejmujaca ten wektor komórka gospodarza oraz sposoby wytwarzania urykazy oraz zawierajacej urykaze kompozycji farmaceutycznej |
EP1899486A4 (en) | 2005-06-08 | 2009-07-22 | Millennium Pharm Inc | METHOD FOR IDENTIFYING, ASSESSING AND TREATING PATIENTS IN CANCER THERAPY |
GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
CA2618479C (en) | 2005-08-26 | 2014-12-30 | Laboratoires Serono S.A. | Pyrazine derivatives and use as pi3k inhibitors |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
US20100297673A1 (en) | 2006-09-20 | 2010-11-25 | Reddy Us Therapeutics | Methods and compositions for upregulation of peroxiredoxin activity |
US20080109846A1 (en) | 2006-10-23 | 2008-05-08 | Ewertz C Christian | System and method for audiovisual content playback |
US7906555B2 (en) | 2006-10-26 | 2011-03-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
CN101679371A (zh) | 2006-12-04 | 2010-03-24 | 艾美罗股份公司 | 作为腺苷受体拮抗剂的取代的嘧啶 |
PT2101760E (pt) | 2006-12-08 | 2013-05-07 | Millennium Pharm Inc | Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa |
US7858782B2 (en) | 2006-12-15 | 2010-12-28 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
CN101679321B (zh) | 2007-04-30 | 2012-10-03 | 普罗米蒂克生物科学公司 | 三嗪衍生物、含所述衍生物的组合物以及所述衍生物在制备用于治疗癌症和自身免疫性疾病药物中的应用 |
JP2010529193A (ja) | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
CN103923072B (zh) | 2007-07-20 | 2017-05-31 | 内尔维阿诺医学科学有限公司 | 作为具有激酶抑制剂活性的取代的吲唑衍生物 |
WO2009015254A1 (en) | 2007-07-25 | 2009-01-29 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
TW200906818A (en) | 2007-07-31 | 2009-02-16 | Astrazeneca Ab | Chemical compounds |
US20090163508A1 (en) | 2007-10-10 | 2009-06-25 | Takeda Pharmaceutical Company Limited | Amide compound |
WO2009051910A1 (en) * | 2007-10-16 | 2009-04-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
JP5277685B2 (ja) | 2008-03-26 | 2013-08-28 | 富士ゼロックス株式会社 | 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法 |
GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
CN101575408B (zh) | 2008-05-09 | 2013-10-30 | Mca技术有限公司 | 用作阻燃剂和光稳定剂的聚三嗪基化合物 |
AU2009246926B2 (en) | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
FR2932483A1 (fr) | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
WO2010007756A1 (ja) | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Ttk阻害作用を有するピリジン誘導体 |
JP5421374B2 (ja) | 2008-09-03 | 2014-02-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 悪性神経膠腫におけるイソクエン酸デヒドロゲナーゼ遺伝子および他の遺伝子の遺伝子変化 |
US20100144722A1 (en) | 2008-09-03 | 2010-06-10 | Dr. Reddy's Laboratories Ltd. | Novel heterocyclic compounds as gata modulators |
JP2010079130A (ja) | 2008-09-29 | 2010-04-08 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
WO2010059239A2 (en) | 2008-11-21 | 2010-05-27 | Millennium Pharmaceuticals, Inc | Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
JP2010181540A (ja) | 2009-02-04 | 2010-08-19 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
KR101677778B1 (ko) | 2009-02-06 | 2016-11-18 | 니뽄 신야쿠 가부시키가이샤 | 아미노피라진 유도체 및 의약 |
CN102985557B (zh) | 2009-03-13 | 2018-06-15 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
DK2427441T3 (en) | 2009-05-04 | 2017-03-20 | Agios Pharmaceuticals Inc | PKM2 Activators for use in the treatment of cancer |
WO2010130638A1 (en) | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
JP2012529511A (ja) | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | トリアジン誘導体類及びそれらの治療応用 |
BRPI1011527A2 (pt) | 2009-06-09 | 2016-07-26 | California Capital Equity Llc | derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. |
WO2010144404A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Pyridil-triazine inhibitors of hedgehog signaling |
EP2448582B1 (en) | 2009-06-29 | 2017-04-19 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
US20120197411A1 (en) | 2009-07-10 | 2012-08-02 | Milux Holding Sa | Knee joint device and method |
JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
CA2773561A1 (en) | 2009-09-14 | 2011-03-17 | Phusis Therapeutics Inc. | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
JP5473851B2 (ja) | 2009-09-30 | 2014-04-16 | 富士フイルム株式会社 | 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置 |
US8652534B2 (en) | 2009-10-14 | 2014-02-18 | Berry Pharmaceuticals, LLC | Compositions and methods for treatment of mammalian skin |
ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
WO2011047432A1 (en) | 2009-10-22 | 2011-04-28 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
JP5967827B2 (ja) | 2009-12-09 | 2016-08-10 | アジオス ファーマシューティカルズ, インコーポレイテッド | Idh変異体をもつことを特徴とする癌治療用の治療的活性化合物 |
NZ578968A (en) | 2010-02-10 | 2011-03-31 | Allans Sheetmetal And Engineering Services | Fuel feed system for a pellet fire |
EP2553116A4 (en) | 2010-04-01 | 2013-10-23 | Agios Pharmaceuticals Inc | METHOD FOR IDENTIFYING A CANDIDATE COMPOUND |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
AU2011278998B2 (en) | 2010-07-16 | 2016-06-09 | Les Laboratoires Servier | Therapeutically active compositions and their method of use |
SI2630146T1 (sl) | 2010-10-21 | 2020-12-31 | Medivation Technologies Llc | Kristalinična tosilatna sol (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)- 8,9-dihidro-2H-pirido(4,3,2-DE)ftalazin-3(7H)-ON |
WO2012078288A2 (en) | 2010-11-08 | 2012-06-14 | Washington University | Methods of determining risk of adverse outcomes in acute myeloid leukemia |
KR20140049961A (ko) | 2010-11-29 | 2014-04-28 | 갈레온 파마슈티칼스, 인코포레이티드 | 호흡 조절 장애 또는 질병의 치료를 위한 호흡 자극제로서의 신규 화합물 |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
WO2012173682A2 (en) | 2011-03-29 | 2012-12-20 | The Broad Institute, Inc. | Compounds and methods for the treatment of isocitrate dehydrognase related diseases |
JP6267112B2 (ja) | 2011-05-03 | 2018-01-24 | アジオス ファーマシューティカルズ, インコーポレイテッド | ピルビン酸キナーゼアクチベーターの使用方法 |
TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
CA2834610A1 (en) | 2011-06-06 | 2012-12-13 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CA2840883C (en) | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
ES2627120T3 (es) | 2011-07-08 | 2017-07-26 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicamento para el tratamiento del cáncer de hígado |
US9167820B2 (en) | 2011-07-22 | 2015-10-27 | University Of Louisville Research Foundation, Inc. | Anti-biofilm compounds |
KR20140069235A (ko) | 2011-09-27 | 2014-06-09 | 노파르티스 아게 | 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
CN102659765B (zh) | 2011-12-31 | 2014-09-10 | 沈阳药科大学 | 嘧啶及三嗪类化合物的制备方法和应用 |
NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
JP6228130B2 (ja) | 2012-01-19 | 2017-11-08 | アジオス ファーマシューティカルズ, インコーポレイテッド | 治療活性化合物およびそれらの使用方法 |
EP2634259A1 (en) | 2012-03-01 | 2013-09-04 | Deutsches Krebsforschungszentrum | Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG) |
WO2013133367A1 (ja) | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | 新規トリアジン誘導体 |
WO2014015422A1 (en) | 2012-07-27 | 2014-01-30 | Ontario Institute For Cancer Research | Cellulose-based nanoparticles for drug delivery |
CN104822373B (zh) | 2012-10-15 | 2018-08-28 | 安吉奥斯医药品有限公司 | 治疗性化合物和组合物 |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015127173A1 (en) | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
AU2015229214B2 (en) | 2014-03-14 | 2019-07-11 | Les Laboratoires Servier | Pharmaceutical compositions of therapeutically active compounds |
BR122023021436A2 (pt) | 2014-03-14 | 2023-12-12 | Les Laboratoires Servier | Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos |
SI3362066T1 (sl) | 2015-10-15 | 2022-04-29 | Les Laboratoires Servier | Kombinirana terapija za zdravljenje malignosti |
KR20180061372A (ko) | 2015-10-15 | 2018-06-07 | 아지오스 파마슈티컬스 아이엔씨. | 악성 종양의 치료를 위한 조합물 요법 |
CA3007218A1 (en) | 2015-12-04 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Methods of treatment of malignancies |
WO2017146794A1 (en) | 2016-02-26 | 2017-08-31 | Celgene Corporation | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
-
2013
- 2013-01-18 US US13/745,005 patent/US9474779B2/en active Active
- 2013-01-21 WO PCT/CN2013/000068 patent/WO2013107291A1/en active Application Filing
- 2013-01-21 CA CA2861556A patent/CA2861556C/en active Active
- 2013-01-21 EA EA201491391A patent/EA026723B1/ru unknown
- 2013-01-21 HU HUE13738319A patent/HUE039110T2/hu unknown
- 2013-01-21 PL PL18183579T patent/PL3447052T3/pl unknown
- 2013-01-21 RS RS20181025A patent/RS57730B1/sr unknown
- 2013-01-21 TW TW102102190A patent/TWI636040B/zh active
- 2013-01-21 ES ES13738319.6T patent/ES2685746T3/es active Active
- 2013-01-21 EP EP21203128.0A patent/EP3985001A1/en active Pending
- 2013-01-21 TW TW107116320A patent/TWI713847B/zh active
- 2013-01-21 KR KR1020197033106A patent/KR102108507B1/ko active IP Right Grant
- 2013-01-21 SG SG10202103521PA patent/SG10202103521PA/en unknown
- 2013-01-21 UA UAA201409238A patent/UA115047C2/uk unknown
- 2013-01-21 PE PE2019000472A patent/PE20190801A1/es not_active Application Discontinuation
- 2013-01-21 NZ NZ722400A patent/NZ722400A/en unknown
- 2013-01-21 IN IN5986DEN2014 patent/IN2014DN05986A/en unknown
- 2013-01-21 PT PT181835794T patent/PT3447052T/pt unknown
- 2013-01-21 LT LTEP13738319.6T patent/LT2804851T/lt unknown
- 2013-01-21 MY MYPI2014002104A patent/MY178486A/en unknown
- 2013-01-21 SI SI201331959T patent/SI3447052T1/sl unknown
- 2013-01-21 DK DK13738319.6T patent/DK2804851T3/en active
- 2013-01-21 KR KR1020207012665A patent/KR102144739B1/ko active IP Right Grant
- 2013-01-21 CN CN201610805857.XA patent/CN106496090B/zh active Active
- 2013-01-21 AU AU2013211436A patent/AU2013211436B2/en active Active
- 2013-01-21 MX MX2014008744A patent/MX351166B/es active IP Right Grant
- 2013-01-21 AR ARP130100177A patent/AR089768A1/es active IP Right Grant
- 2013-01-21 KR KR1020147022964A patent/KR102044730B1/ko active IP Right Grant
- 2013-01-21 CA CA3077245A patent/CA3077245A1/en not_active Abandoned
- 2013-01-21 EA EA201692271A patent/EA035662B1/ru unknown
- 2013-01-21 SG SG10201608374XA patent/SG10201608374XA/en unknown
- 2013-01-21 HU HUE18183579A patent/HUE057264T2/hu unknown
- 2013-01-21 ES ES18183579T patent/ES2903390T3/es active Active
- 2013-01-21 CR CR20170097A patent/CR20170097A/es unknown
- 2013-01-21 PT PT13738319T patent/PT2804851T/pt unknown
- 2013-01-21 UA UAA201700262A patent/UA122324C2/uk unknown
- 2013-01-21 CN CN201380009364.XA patent/CN104136411B/zh active Active
- 2013-01-21 HR HRP20220017TT patent/HRP20220017T1/hr unknown
- 2013-01-21 LT LTEP18183579.4T patent/LT3447052T/lt unknown
- 2013-01-21 SI SI201331138T patent/SI2804851T1/sl unknown
- 2013-01-21 EP EP18183579.4A patent/EP3447052B1/en active Active
- 2013-01-21 BR BR112014017840-2A patent/BR112014017840B1/pt active IP Right Grant
- 2013-01-21 PL PL13738319T patent/PL2804851T3/pl unknown
- 2013-01-21 PE PE2014001128A patent/PE20141824A1/es active IP Right Grant
- 2013-01-21 EP EP13738319.6A patent/EP2804851B1/en active Active
- 2013-01-21 RS RS20220030A patent/RS62919B1/sr unknown
- 2013-01-21 JP JP2014552489A patent/JP6313714B2/ja active Active
- 2013-01-21 SG SG11201404190PA patent/SG11201404190PA/en unknown
- 2013-01-21 DK DK18183579.4T patent/DK3447052T3/da active
- 2013-01-21 NZ NZ627053A patent/NZ627053A/en unknown
-
2014
- 2014-07-15 PH PH12014501626A patent/PH12014501626A1/en unknown
- 2014-07-17 CL CL2014001891A patent/CL2014001891A1/es unknown
- 2014-07-17 IL IL233683A patent/IL233683B/en active IP Right Grant
- 2014-07-18 CO CO14156115A patent/CO7010834A2/es unknown
- 2014-07-18 NI NI201400078A patent/NI201400078A/es unknown
- 2014-08-18 EC ECIEPI201414544A patent/ECSP14014544A/es unknown
- 2014-08-18 CR CR20140388A patent/CR20140388A/es unknown
- 2014-11-26 HK HK14111932.2A patent/HK1198439A1/xx unknown
-
2016
- 2016-01-05 US US14/988,661 patent/US20160130298A1/en not_active Abandoned
- 2016-09-28 US US15/279,146 patent/US9850277B2/en active Active
-
2017
- 2017-02-28 JP JP2017036691A patent/JP2017101067A/ja not_active Withdrawn
- 2017-08-08 PH PH12017501419A patent/PH12017501419A1/en unknown
- 2017-11-10 US US15/809,325 patent/US10640534B2/en active Active
- 2017-11-23 AU AU2017265100A patent/AU2017265100B2/en active Active
-
2018
- 2018-06-29 PH PH12018501410A patent/PH12018501410A1/en unknown
- 2018-07-27 HR HRP20181199TT patent/HRP20181199T1/hr unknown
- 2018-09-04 CY CY181100915T patent/CY1120651T1/el unknown
- 2018-11-02 JP JP2018207185A patent/JP6805220B2/ja active Active
-
2019
- 2019-01-28 IL IL264516A patent/IL264516B/en active IP Right Grant
- 2019-05-31 US US16/427,691 patent/US10717764B2/en active Active
- 2019-12-19 AU AU2019283951A patent/AU2019283951B2/en active Active
-
2020
- 2020-06-05 US US16/893,750 patent/US11667673B2/en active Active
- 2020-11-30 JP JP2020198026A patent/JP2021038263A/ja not_active Withdrawn
-
2021
- 2021-01-19 ZA ZA2021/00373A patent/ZA202100373B/en unknown
- 2021-03-31 IL IL281942A patent/IL281942B/en unknown
- 2021-07-07 AR ARP210101907A patent/AR122902A2/es unknown
-
2022
- 2022-01-19 CY CY20221100045T patent/CY1124988T1/el unknown
-
2023
- 2023-02-17 US US18/111,511 patent/US20240059733A1/en active Pending
- 2023-09-07 FR FR23C1031C patent/FR23C1031I1/fr active Active
- 2023-09-18 NL NL301243C patent/NL301243I2/nl unknown
- 2023-10-10 HU HUS2300035C patent/HUS2300035I1/hu unknown
- 2023-10-10 FI FIC20230031C patent/FIC20230031I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP14014544A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
ECSP14012726A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
CR20160069A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
MX350432B (es) | Compuestos terapeuticamente activos y sus metodos de empleo. | |
CO2019005287A2 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
CR20150316A (es) | Compuestos y sus métodos de empleo | |
CR20150571A (es) | Compuestos y composiciones terapéuticos | |
CL2013003638A1 (es) | Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas. | |
BR112016002287A2 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
UY34395A (es) | ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?. | |
AR089993A1 (es) | Macrociclos peptidomimeticos | |
UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
CR20150390A (es) | Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2) | |
UY34165A (es) | ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?. | |
UY34216A (es) | Nuevos compuestos que inhiben la actividad de la Lp-PLA2 | |
MX2021001425A (es) | Compuestos terapeuticos activos y sus usos. | |
EA201400990A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 | |
UY34406A (es) | Compuestos y métodos para mejorar la respuesta inmune innata | |
BR112015003957A2 (pt) | alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria | |
UY35823A (es) | Profármacos de antagonista de nmda | |
CR20160054A (es) | Compuestos terapeuticamente activos y sus métodos de uso | |
AR098781A1 (es) | Compuestos peptidomiméticos y conjugados anticuerpos-droga de los mismos | |
RU2012144184A (ru) | Применение препаратов гуминовых кислот в качестве ингибиторов липазы |